UnitedHealth Group (UNH) just delivered the quarter battered shareholders have been waiting for.
The health care company blew past Wall Street‘s profit prediction, increased its most widely monitored cost index, and boosted its full-year earnings outlook. The results seemed to vindicate investors who had bought the stock during the collapse of confidence in the company.
But UnitedHealth’s recovery isn’t over.
The corporation continues to face federal review of its Medicare billing methods, and management has warned that pressure on medical costs will remain. This leaves investors with a tough question: Is UnitedHealth reverting to its old earnings machine, or is the stock rallying because the biggest risk is now out of the way?
Investor Steve Weiss has continued to buy UnitedHealth, calling it a “permanent compounder” on CNBC. Billionaire investor Bill Ackman had the opposite view, warning the company’s mounting problems could expose deeper trouble.
Weiss has recent earnings on his side, while the government probes prohibit investors from giving up on Ackman.
UnitedHealth’s earnings destroyed the bearish operating case
UnitedHealth reported second-quarter adjusted earnings of $6.38 a share, according to Reuters, well above the $4.90 analysts were expecting. Revenue was $112 billion, above consensus and up a little over last year.
The company also boosted its projection for 2026 adjusted earnings to a range of $19.50 to $20 per share, from a previous view of at least $18.25.
Related: JPMorgan resets UnitedHealth stock target for 2026
Earnings were not the most important number; it was the medical loss ratio for UnitedHealth.
The ratio, which tracks the percentage of premium revenue used for members’ medical treatment, improved to 86.7% from 89.4% a year earlier and was well below expectations of analysts, Reuters noted.
If health costs are lower, an insurer can retain a larger share of the premium revenue for administrative expenditures and profit.
The improvement shows that UnitedHealth’s plan redesigns, pricing measures, and medical-management strategies are starting to take hold.
Optum offered another positive indicator. Operating income in the health services unit soared 29% to almost $4 billion, Reuters confirmed, quashing fears that the problems had infected more than the insurance business.
One number makes UnitedHealth’s recovery less reassuring
UnitedHealth’s 86.7% medical care ratio comprised about $860 million of favorable prior-period development. That indicates some of the improvement came from the corporation modifying projections for medical claims from earlier periods, not just from decreased costs incurred during the quarter.
This does not make the result invalid. Still, investors should not expect all of the margin improvement to be a permanent change in the underlying business.
Management also said medical cost trends remain elevated in Medicare and commercial insurance, Investors Business Daily noted, mainly driven by specialty pharmaceuticals and costs related to the No Surprises Act. UnitedHealth’s raised earnings outlook was still below some analyst projections, helping the stock give back much of its initial post-results rally.
UnitedHealth is likewise cutting back on its less profitable Medicare Advantage plans. Such moves can restore margins, but there’s a trade-off: fewer members, and maybe slower revenue growth.
So the essence of the turnaround is that UnitedHealth is making more money from a smaller, more worth-its-price membership.
The threat UnitedHealth’s earnings cannot resolve
The Justice Department has investigated UnitedHealth’s Medicare Advantage billing practices, including how diagnoses sent to the government could affect payments.
UnitedHealth said in 2025 that it was responding to official civil and criminal requests and said it had confidence in the integrity of its processes. An investigation doesn’t imply any wrongdoing, and you shouldn’t make any assumptions until the process is complete.
But it cuts to the core of UnitedHealth’s business model.
Insurers who offer Medicare Advantage plans receive paid extra for people with serious health issues. Governments immediately penalized for illegal payments resulting from coding practices could face financial penalties, operational modifications, or reputational damage.
That’s the heart of the bearish thesis. It is not that UnitedHealth cannot improve one quarter’s medical costs. It is that the market still cannot confidently estimate the potential cost of federal scrutiny.
Key takeaways for UnitedHealth investors
- Adjusted earnings substantially exceeded Wall Street’s forecast.
- The medical care ratio improved to 86.7%.
- Optum’s operating income increased 29%.
- UnitedHealth raised its 2026 earnings outlook.
- Some cost improvement came from favorable prior-period development.
- Federal Medicare scrutiny remains unresolved.
UnitedHealth already answered the first question investors asked after its crash — namely, whether the corporation can still make a lot of money.
It has not answered the more critical question: whether the practices, laws, and medical-cost assumptions enabling those earnings will stay in place. That makes UnitedHealth’s recovery especially difficult to value.
The operating recuperation is real. The momentum in earnings is picking up. And the latest revelation weakened the argument that the business is permanently broken.
But one good quarter doesn’t close a federal inquiry.
UnitedHealth’s stock could continue to climb as margins improve. The danger is that investors are pricing the turnaround faster than anyone can price what investigators may eventually find.
Related: UnitedHealth CFO sends stark warning after earnings
